A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

463

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

June 19, 2019

Study Completion Date

September 19, 2019

Conditions
Migraine
Interventions
DRUG

Galcanezumab

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (69)

1083

SE Neurologiai Klinika, Budapest

1090

Universitair Ziekenhuis Brussel, Brussels

1145

Orszagos Idegtudomanyi Intezet, Budapest

2500

Valeomed Kft., Esztergom

8000

Algemeen Ziekenhuis St Jan Brugge, Bruges

10117

Charité Universitätsmedizin Berlin, Berlin

14609

Rochester Clinical Research, Inc., Rochester

18104

Lehigh Center for Clinical Research, Allentown

18600

Institut Neuropsychiatricke Pece, Prague

23606

Health Research of Hampton Roads Inc, Newport News

27201

Brain-Soultherapy s.r.o, Kladno

27408

PharmQuest, Greensboro

29464

Coastal Carolina Research Center, Inc., Mt. Pleasant

33544

Renstar Medical Research, Wesley Chapel

33612

University of South Florida, Tampa

34121

DRK-Kliniken Nordhessen, Kassel

34761

Sensible Healthcare, Ocoee

39008

Hospital Universitario Marques De Valdecilla, Santander

42000

CHU St Etienne Hopital Nord, Saint-Etienne

44787

Praxis Dr. Philipp Stude, Bochum

45147

Universitätsklinikum Essen, Essen

46010

Hospital Clínico Universitario de Valencia, Valencia

46026

Hospital Universitario La Fe de Valencia, Valencia

47010

Hospital Clinico Universitario de Valladolid, Valladolid

48104

Michigan Head, Pain and Neurological Institute, Ann Arbor

55402

Clinical Research Institute, Minneapolis

59037

CHRU de Lille- Hôpital Roger Salengro, Lille

84109

Foothill Family Clinic, Salt Lake City

85004

21st Century Neurology, Phoenix

87102

Albuquerque Clinical Trials, Albuquerque

92108

Medical Center for Clinical Research, San Diego

5560017

Tominaga Hospital, Osaka

02131

Boston Clinical Trials, Boston

03060

Healthy Perspectives Innovative Mental Health Services, PL, Nashua

08755

Bio Behavioral Health, Toms River

98007-4209

Northwest Clinical Research Center, Bellevue

B-9000

Universitair Ziekenhuis Gent, Ghent

V1Y 1Z9

Okanagan Clinical Trials, Kelowna

L6T 0G1

Aggarwal and Associates Ltd, Brampton

J1H 1Z1

DIEX Recherche Sherbrooke, Inc, Sherbrooke

100 00

Clintrial, s.r.o., Prague

616 00

Neurologicka ambulance, Neurologie Brno s.r.o., Brno

120 00

DADO MEDICAL, s.r.o., Prague

160 00

Neurologicka ordinace, Prague

06000

Hôpital de Cimiez, Nice

07747

Universitätsklinikum Jena, Jena

003-0003

Higashi Sapporo Neurology and Neurosurgery Clinic, Sapporo

780-0051

Medical corporation Shinmatsudakai Atago Hospital, Kochi

982-0014

Sendai Headache and Neurology Clinic, Sendai

560-0012

Takase internal medicine clinic, Toyonaka-shi

321 0293

Dokkyo Medical University Hospital, Shimotsuga-Gun

160-0017

Fukuuchi Pain Clinic, Shinjuku-ku

680-0045

Shimoda Neurology Clinic, Tottori-shi

730-0031

Doi Clinic Internal Medicine Neurology, Hiroshima

892-0844

Tanaka neurosurgical clinic, Kagoshima

600-8811

Tatsuoka Neurology Clinic, Kyoto

870-0831

Ooba Clinic for Neurosurgery & Headache, Ōita

6532 SZ

Canisius-Wilhelmina Ziekenhuis, Nijmegen

8025 AB

Isala Klinieken, Zwolle

00918

Instituto de Neurologia Dra. Ivonne Fraga, San Juan

01830

Nowon Eulji Medical Center, Eulji University, Seoul

03080

Seoul National University Hospital, Seoul

03181

Kangbuk Samsung Hosp, Seoul

120-792

Severance Hospital Yonsei University Health System, Seoul

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

08035

Hospital Universitari Vall d'Hebron, Barcelona

HU3 2JZ

Hull Royal Infirmary, Hull

SE5 9RS

Kings College Hospital, London

SE1 7EH

St Thomas's Hospital, London

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03559257 - A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine | Biotech Hunter | Biotech Hunter